Citron Research, famed for short selling reports, are recommending long this stock – Schrodinger (SDRG).
They describe it as – “the most disruptive software platform to ever hit the pharmaceutical industry, which also happens to be backed by the world’s most sophisticated investors, has just gone public.“
Looks interesting and is worth investigating. The shares are sadly ca. +100% since IPO already.
As always with investing – this is not a recommendation, do your own work, use common sense.
